Neurocrine Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Neurocrine Biosciences (NBIX).

Price Target Range — 7 Quarters

Analyst Consensus — 23 Analysts

21Buy

2Hold

Consensus RatingBuy# Analysts23Avg. Consensus PT$200Upside to Avg. PT+37.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 6, 2026	Guggenheim	Delma Caiati	Assumes	Buy	$207
Sep 29, 2026	UBS	Ashwani Verma	PT Cut	Buy	$231→$214
Sep 11, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Equal-Weight	$182→$183
Sep 8, 2026	RBC Capital	Brian Abrahams	Maintained	Outperform	$198
Sep 3, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$249→$253
Aug 13, 2026	Morgan Stanley	Jeffrey Hung	PT Cut	Equal-Weight	$196→$182
Aug 3, 2026	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$200→$210
Aug 3, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$200→$213
Aug 3, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$185→$194
Jul 31, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$246→$249
Jul 31, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$195→$198
Jul 31, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Equal-Weight	$193→$196
Jul 31, 2026	TD Cowen	Phil Nadeau	PT Raise	Buy	$200→$220
Jul 31, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$207→$210
Jul 31, 2026	Cantor Fitzgerald	Josh Schimmer	PT Raise	Overweight	$210→$215
Jul 31, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$200→$222
Jul 31, 2026	Stifel	Paul Matteis	PT Raise	Buy	$188→$215
Jul 31, 2026	Needham	Ami Fadia	PT Raise	Buy	$200→$204
Jul 21, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$175→$200
Jul 17, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$175→$200

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207

Guggenheim analyst Delma Caiati assumes Neurocrine Biosciences (NASDAQ:NBIX) with a Buy rating and announces Price Target of $207.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214

UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $231 to $214.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $182 to $183.

Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target

RBC Capital analyst Brian Abrahams reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and maintains $198 price target.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253

Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $249 to $253.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and lowers the price target from $196 to $182.

Benzinga Newsdesk

Neurocrine Biosciences Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Neurocrine Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207

PRO
UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183

PRO
RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target

PRO
Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182

People Also Watch

People Also Watch

Neurocrine Biosciences Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Neurocrine Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207

PROUBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214

PROMorgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183

PRORBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target

PROCitigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253

PROMorgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182

People Also Watch

People Also Watch

PRO
Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207

PRO
UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183

PRO
RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target

PRO
Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182